In monster MASH takeover deal, Novo buys Akero for $4.7bn скачать в хорошем качестве

In monster MASH takeover deal, Novo buys Akero for $4.7bn

In today’s headlines – 9 October: Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease. The regulatory authorities in the UK and US have agreed to work more closely together on the regulation of medical technologies and AI. Changes to the threshold used by NICE to measure cost-effectiveness could be on the way as part of a plan that would raise NHS spending on medicines. Amazon's latest bid to disrupt the healthcare market in the US will see the introduction later this year of electronic drug dispensing kiosks. Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma. Subscribe to ‪@Pharmaphorum‬ for daily news updates and check out www.pharmaphorum.com for more insights and analysis. #news #pharma #pharmanews #pharmainnovation #pharmaindustry #lifesciences #biotechnews #biopharma #drugdevelopment #drugdiscovery #novonordisk #akero #mash #wegovy #liverdisease #medtech #ai #nice #ukhealthcare #nhs #drugprices #drugpricing #amazon #regeneron #fda #fdaapproval #carcinoma As an official Frontiers Health conference partner, we are pleased to offer pharmaphorum readers an exclusive 20% discount. Don’t miss this unique opportunity to engage with some of the brightest minds in modern healthcare to discuss the biggest trends, opportunities, and challenges facing today’s health innovators. Click below and use promo code: FH25PHP20 to register at a reduced price: https://www.frontiers.health/2025-reg...